Elevance Health (ELV)今日盘中股价大跌5.08%，引发市场广泛关注。此次股价下跌主要受到多家华尔街知名券商下调公司评级和目标价的影响。
据悉，杰富瑞证券将Elevance Health的目标价从488美元大幅下调至370美元，降幅达24%。与此同时，Leerink Partners更是采取了更为激进的措施，不仅将目标价从510美元下调至310美元，降幅高达39%，还将公司评级从"跑赢大盘"直接下调至"跑输大盘"。这些举动反映出分析师对该公司未来业绩表现的担忧。
这些券商的评级和目标价调整对投资者信心造成了明显打击。尽管Elevance Health尚未发布任何重大负面消息，但分析师的悲观态度已足以引发市场对公司基本面的质疑。投资者可能需要密切关注公司未来的财报表现和业务发展，以评估此次股价调整是否合理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.